Press Releases

Home > Press Releases

Press Releases (Page 3)

Allarity Therapeutics Announces Appointment of New Auditor

Press release     Cambridge, MA U.S.A. (September 12, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, announced today the appointment of Wolf & Company, P.C. (Boston, MA) (“Wolf & Company”) as the Company’s... ❯❯❯

AdCare Rhode Island Named Fastest Growing Companies Finalist by Providence Business News

NORTH KINGSTOWN, R.I., Sept. 09, 2022 (GLOBE NEWSWIRE) -- AdCare Rhode Island is excited to be recognized for the second consecutive year as a Providence Business News Fastest Growing Companies finalist in the $5 million to $25 million category. Fred Trapassi, Jr., CEO, attributes growth achieved in 2021 to “their extremely knowledgeable and motivated staff who are dedicated to helping individuals struggling with addiction; the... ❯❯❯

The Good Clinic Expands Services with Pharmacogenetic Testing by Xact Laboratories

XactMed4U™ offers precision medicine technology to determine the effectiveness of medication through pharmacogenomics Minneapolis, MN, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- The Good Clinic™ is deepening its service offerings to include pharmacogenomic testing through Xact Laboratories, an Ohio-based biotechnology company focused on providing state-of-the-art molecular diagnostic tests. The product,... ❯❯❯

Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022

NORCROSS, Ga., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 24th Annual Global Investment Conference being held on September 12-14, 2022. The Wainwright Conference brings together thought leaders and practitioners from numerous fields to participate in... ❯❯❯

LifeLabs’ President and CEO named one of the “Top 100 Innovation CEOs of 2022”

Toronto, Ontario, Sept. 07, 2022 (GLOBE NEWSWIRE) -- We are pleased to share that LifeLabs’ President and CEO, Charles Brown, has been named one of the “Top 100 Innovation CEOs of 2022” by the World Biz Magazine.   World Biz Magazine's Top 100 Innovation CEO Awards celebrates business leaders across the globe that are making major strides in their industries. Over 40,000 leaders were shortlisted for this award and the... ❯❯❯

SeaSpine Announces Full Commercial Launch of the WaveForm® TA (TLIF Articulating) Interbody System

CARLSBAD, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of the WaveForm TA (TLIF Articulating) Interbody System. The WaveForm TA Interbody System is designed to deliver an interbody to the anterior portion of the disc space to optimize sagittal... ❯❯❯

Press release Biocartis Group NV: DISCLOSURE OF OUTSTANDING VOTING SECURITIES

PRESS RELEASE: REGULATED INFORMATION 6 September 2022, 17:40 CEST DISCLOSURE OF OUTSTANDING VOTING SECURITIES Mechelen, Belgium, 6 September 2022 – Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces that 810,734 new shares were issued on 6 September 2022 to certain funds and accounts managed or advised by Highbridge Capital Management LLC, and... ❯❯❯

Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that its collaboration with Dr. Iñaki Sanz at Emory University has led to a publication in Nature, found here. Exagen’s clinical test offerings, run on samples from severe COVID-19 patients, helped researchers from Emory characterize the autoimmune profiles induced by SARS-CoV-2 infection. ... ❯❯❯

Press release Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2022 RESULTS

PRESS RELEASE: REGULATED INFORMATION1 September 2022, 07:02 CEST         BIOCARTIS ANNOUNCES H1 2022 RESULTSAffirms 2022 Outlook 35% growth in oncology cartridge revenues Gross Margin on Products of 32%Refinancing underway Company will host a conference call with live webcast presentation today at 14:30 CEST / 13:30 BST (UK) / 08:30 EDT (US) to discuss H1 2022 results Mechelen, Belgium, 1 September 2022 – Biocartis... ❯❯❯

Press release Biocartis Group NV: Biocartis Initiates Commercialization in Europe of SkylineDx’s Innovative Merlin™ Assay (CE-IVD) for Melanoma Patients

PRESS RELEASE: 1 September 2022, 07:01 CEST Biocartis Initiates Commercialization in Europe of SkylineDx’s Innovative Merlin™ Assay (CE-IVD) for Melanoma PatientsMerlin helps identify melanoma patients who may safely forgo the sentinel lymph node biopsy Melanoma is the deadliest form of skin cancer1Biocartis to initiate commercialization in Europe of SkylineDx’s innovative Merlin Assay, ahead of the launch of an Idylla™... ❯❯❯